Pharmaceuticals
Novartis, Amgen, and Eli Lilly are racing to address Lp(a), a genetic cardiovascular risk factor affecting 1 in 5 people with no approved treatment. The first pivotal outcomes data could arrive within weeks.
Biotechnology
The FDA's approval of Rasonque marks a watershed moment in oncology—the first therapy to directly target RAS, ending three decades of failed attempts to drug one of cancer's most intractable targets.
Pharmaceuticals
Takeda's FDA approval of Orzeyful marks a paradigm shift in narcolepsy treatment—the first medicine to directly target orexin deficiency rather than manage symptoms.
Biotechnology
Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.
Pharmaceuticals
The FDA approved a subcutaneous starting dose of lecanemab, allowing Alzheimer's patients to begin treatment at home via weekly self-injection—removing a major access barrier to this disease-modifying therapy.
Biotechnology
The FDA's accelerated approval of Ultragenyx's Genglycos marks the first gene therapy for glycogen storage disease type Ia, signaling a new era in treating rare metabolic diseases at their genetic root.
Wall Street Wire
Moderna's cancer vaccine with Keytruda just worked. That's huge: the stock nearly tripled, and the whole biotech index moved. As attention around oncology innovators increases, several other companies are doing exciting things that may be worth watching.
Biotechnology
Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene has succeeded in its first Phase 3 trial in melanoma, marking the first late-stage win for any mRNA cancer vaccine and raising profound questions about the future of oncology and the mRNA platform itself.
Policy
The FDA's new discussion paper on generative AI-enabled medical devices proposes evaluating AI systems the way physicians are evaluated. The implications for medtech, digital health, and the future of clinical AI are significant.
Biotechnology
AstraZeneca discontinues Phase 3 trial of volrustomig, its PD-1/CTLA-4 bispecific antibody in lung cancer, revealing structural challenges in displacing Keytruda and diverging fortunes in the bispecific antibody race.
Biotechnology
Epicrispr's EPI-321 produced measurable muscle growth in FSHD patients with a single dose, without altering DNA. The $90M Series C and early clinical data mark a potential inflection point for epigenetic medicine.
Biotechnology
Definium Therapeutics' Phase 3 Voyage trial shows DT120, a pharmaceutically optimized LSD formulation, achieved an 11.6-point reduction in anxiety scores—the strongest placebo-adjusted efficacy benefit ever observed in a pivotal GAD study.